TABLE 2.
Comparison of CMV-specific immune responses in SIV-infected rhesus macaques with and without CMV disease
| CMV disease (n) | Anti-CMV binding Ab titera
|
Anti-CMV 50% neutralizing Ab titer
|
CMV-specific CD4+ T cells (SFC/106 CD4+ cells)
|
CMV-specific CD8+ T cells (SFC/106 PBMCs)
|
||||
|---|---|---|---|---|---|---|---|---|
| Pre-SIV infectionc | At time of deathc | Pre-SIV infection | At time of death | Pre-SIV infection | At time of death | Pre-SIV infection | At time of death | |
| Present (6) | 1,000 (400-3,200) | 300 (200-800) | 3,425 (1,650-9,350) | 1,700 (600-3,100) | 1,054 (428-2,788) | 2 (0-18) | 617 (395-1,368) | 68 (0-134) |
| Absent (5) | 800 (80-6,400) | 1,600 (800-6,400) | 2,600 (800-12,800) | 2,500 (2,100-5,000) | 707 (187-1,258) | 93 (0-3,086) | 349 (188-665) | 133 (48-1,361) |
| P valueb | 0.93 | 0.01∗ | 0.58 | 0.14 | 0.47 | 0.08 | 0.03∗ | 0.10 |
a
End-point dilution titer.
b
Mann-Whitney U test comparing macaques with and without CMV disease. Asterisks indicate significant P values.
c
Median (range) values are shown.